GLP-1 medicines in Australia: the full picture.
Your week, cooked
7 meals · 38g protein on average · food, not medicine
Delivered chilled across Sydney, Melbourne and Brisbane metro.
First box $79.65 with PLAN20 (new customers, added for you at checkout). Then $99.65 a week for 7 meals with delivery — skip, pause or cancel before any weekly cutoff. Make it 8 meals and delivery is free ($103.60 all in).
4.6 · 438 verified ratings · Skip or cancel anytime · SYD · MEL · BNE
GLP-1 receptor agonists are the medicines behind the brand names Ozempic, Wegovy, Mounjaro and others. This page lists every GLP-1-based medicine registered in Australia, what each is approved for, which are subsidised, what is in the pipeline, how many Australians use them, and what the safety record shows. It is information, not advice.
Six GLP-1-based medicines are registered and supplied in Australia as of 1 October 2026: Ozempic, Wegovy and Rybelsus (semaglutide), Mounjaro (tirzepatide), Trulicity (dulaglutide) and Victoza (liraglutide). Only Ozempic and Trulicity are PBS-subsidised, and only for type 2 diabetes; a restricted Wegovy listing has been recommended but not commenced. All are prescription-only; pharmacy compounding of the class has been banned since 1 October 2024. Update, 9 November 2026: the TGA registered Wegovy semaglutide tablets on 3 November 2026 (not yet released), and the PBAC considered a revised Wegovy listing at its 4–6 November 2026 meeting (outcome not yet published).
- 1 October 2024: Pharmacy compounding of GLP-1 analogues banned. TGA media release.
- 18 July 2025: Ozempic removed from the TGA medicine shortage list. Novo Nordisk Australia product update.
- November 2025: PBAC recommended a restricted Wegovy listing and a “slow and managed roll-out” of subsidised obesity treatment. PBAC advice.
- December 2025: Saxenda (liraglutide 3 mg) withdrawn from Australia; the TGA shortage database records deletion from the market on 19 December 2025. Novo Nordisk letter; TGA shortage database.
- January 2026: Health Minister committed to listing Wegovy; price unresolved as of 1 October 2026. RACGP newsGP.
- July 2026: UNSW study: about 500,000 Australians a month using GLP-1 medicines indicated for type 2 diabetes. UNSW newsroom.
- 3 November 2026: Wegovy semaglutide tablets (1.5, 4, 9 and 25 mg) entered on the ARTG for adult weight management and cardiovascular risk reduction; not yet released as of 9 November 2026. TGA ARTG 522753.
- 4–6 November 2026: PBAC meeting considers a revised Wegovy proposal (established cardiovascular disease, BMI ≥35); outcome not published as of 9 November 2026, scheduled for posting around 18 December 2026. PBS medicine status.
What GLP-1 medicines are.
Glucagon-like peptide-1 (GLP-1) is a hormone released by the gut within minutes of eating. It prompts insulin release when blood glucose rises, suppresses glucagon, slows stomach emptying and signals fullness to the brain. Natural GLP-1 is broken down within minutes; GLP-1 receptor agonists are engineered to activate the same receptor for a day (liraglutide) or a week (semaglutide, dulaglutide, tirzepatide).
The class began in diabetes and expanded into weight management as trials showed sustained appetite reduction. Tirzepatide adds a second target, GIP, making it a dual GIP/GLP-1 receptor agonist. Newer candidates add amylin (CagriSema) or glucagon (retatrutide), or use a swallowable small molecule (orforglipron).
All registered members of the class are Schedule 4 prescription-only medicines.
Every GLP-1-based medicine registered in Australia.
Registration means the TGA has assessed quality, safety and efficacy for the stated indication. It says nothing about subsidy, a separate PBS decision, or whether a medicine suits any individual.
| Brand | Active ingredient | Sponsor | Registered indication | PBS status, 1 Oct 2026 |
|---|---|---|---|---|
| Ozempic | Semaglutide, weekly injection (0.25, 0.5, 1 mg) | Novo Nordisk | Type 2 diabetes (registered 2019) | Listed for type 2 diabetes (authority) since July 2020 |
| Wegovy | Semaglutide 2.4 mg, weekly injection | Novo Nordisk | Chronic weight management (BMI ≥30, or ≥27 with comorbidity); cardiovascular risk reduction in established CVD with BMI ≥27 (December 2024). Launched August 2024. | Not listed; restricted listing recommended November 2025; revised proposal considered at the November 2026 PBAC meeting, outcome pending (9 Nov 2026) |
| Wegovy tablets | Semaglutide tablets (1.5, 4, 9, 25 mg), once daily | Novo Nordisk | Chronic weight management in adults; cardiovascular risk reduction in adults with established CVD, BMI ≥27 and no diabetes (ARTG 3 November 2026). Not for under-18s. Not yet released (9 Nov 2026) | Not listed |
| Mounjaro | Tirzepatide, weekly injection | Eli Lilly | Type 2 diabetes (2022); chronic weight management (2024) | Not listed; type 2 diabetes listing recommended March 2026, sponsor declined April 2026 |
| Rybelsus | Semaglutide tablets (3, 7, 14 mg) | Novo Nordisk | Type 2 diabetes (registered February 2022) | Not listed |
| Trulicity | Dulaglutide, weekly injection | Eli Lilly | Type 2 diabetes | Listed for type 2 diabetes (authority) since June 2018 |
| Victoza | Liraglutide, daily injection | Novo Nordisk | Type 2 diabetes | Not listed; sponsor did not proceed |
| Saxenda | Liraglutide 3 mg, daily injection | Novo Nordisk | Chronic weight management | Never listed; deleted from the market 19 December 2025 (TGA shortage database) |
| Liraglutide generics | Liraglutide 6 mg/mL, daily injection | Several sponsors (eight ARTG entries) | On the ARTG (entries dated March 2025 and February 2026); indications and current supply not confirmed | Not listed (PBS search, 9 Nov 2026) |
| Byetta / Bydureon | Exenatide | AstraZeneca | Type 2 diabetes | No longer supplied; Byetta withdrawn 2022, Bydureon cancelled November 2023 |
Sources: TGA and ARTG records; PBS Schedule; TGA safety update (June 2025); PBAC obesity treatments document (November 2025).
PBS status and the equitable-access advice.
The PBS subsidises GLP-1 medicines for type 2 diabetes only, through Ozempic and Trulicity, under authority criteria a prescriber must confirm; eligible patients pay the standard PBS co-payment. Everything else in the table is supplied on private prescription at a price set by the pharmacy; this page does not report prices.
In March 2025 the Health Minister asked the PBAC how GLP-1 obesity treatments could be made available equitably. Its November 2025 advice, published 19 December 2025, recommended a “slow and managed roll-out” of subsidised access, starting with people with established cardiovascular disease, Aboriginal and Torres Strait Islander people with obesity-related conditions, people with syndromic or medication-induced obesity, and people needing weight loss to qualify for surgery. It cited uncertain long-term outcomes and the risk of subsidised supply leaking outside approved criteria.
At the same meeting the PBAC recommended Wegovy for adults with established cardiovascular disease and obesity, conditional on a price reduction and risk-sharing arrangement. The Minister endorsed the listing in January 2026, but terms had not been agreed with Novo Nordisk as of 1 October 2026. Novo Nordisk then lodged a revised proposal for adults with established cardiovascular disease and a BMI of 35 or more, which the PBAC considered at its 4–6 November 2026 meeting; as of 9 November 2026 the outcome had not been published, and the PBS timetable shows outcomes posted around 18 December 2026. The same meeting’s agenda moved a planned review of GLP-1 use in type 2 diabetes (Ozempic and Trulicity) to a future PBAC meeting (PBAC November 2026 agenda). For Mounjaro, the PBAC recommended a type 2 diabetes listing in March 2026 and Eli Lilly declined in April 2026; no obesity submission has been lodged. Details are in Wegovy and the PBS and tirzepatide in Australia.
What is under evaluation or still in trials.
Approved in the United States in December 2025. The TGA entered Wegovy semaglutide tablets (1.5, 4, 9 and 25 mg) on the ARTG on 3 November 2026 for adult weight management and cardiovascular risk reduction. Not yet released, and no Australian price, as of 9 November 2026.
Eli Lilly’s once-daily oral small-molecule GLP-1 agonist. Accepted for TGA evaluation in January 2026 for weight management and type 2 diabetes; no decision as of 9 November 2026 (TGA list updated 3 November 2026).
A weekly GLP-1 and amylin combination filed with the US FDA in December 2025. Not approved by any regulator as of 1 October 2026.
Eli Lilly’s triple GIP/GLP-1/glucagon agonist. Phase 3 results were reported in 2026; it is not approved anywhere. Products sold online under this name are unapproved and linked to liver injury in Victoria.
Acceptance for TGA evaluation is not approval, and approval is not PBS listing.
How many Australians use them.
Two 2026 analyses measure different things.
UNSW, British Journal of Clinical Pharmacology
Falster and colleagues tracked GLP-1 medicines indicated for type 2 diabetes from May 2020 to April 2025. Monthly use rose from about 58,000 to about 500,000 people, 8.6-fold. Private supply, non-existent in 2020, reached 43.8 per cent of the total.
IQVIA white paper, 2026
From longitudinal dispensing data, IQVIA estimated just over one million unique people, about 5 per cent of Australian adults, were dispensed at least one GLP-1-based obesity medicine in the twelve months to May 2026, all on private prescriptions.
Both describe a market largely outside the PBS, the context for the PBAC’s equity concerns. Neither says whether treatment suits any particular person.
The compounding ban.
During the 2022 to 2025 semaglutide shortage, some pharmacies compounded GLP-1 products at scale under an exemption meant for individual preparations. The TGA judged the ingredients of unknown origin, the practice outside the exemption’s purpose, and the products unevaluated. From 1 October 2024, pharmacists must not compound any medicine containing a GLP-1 receptor agonist analogue, in any dosage form.
Since then the TGA has issued alerts about counterfeit products falsely claiming to contain semaglutide or tirzepatide, warned in April 2026 about unapproved injectable peptides sold online, and in June 2026 named them a compliance priority. Such products have no verified contents, sterility or dose, and no safety reporting.
Side effects and safety communications.
The most common side effects across the class are gastrointestinal: nausea, vomiting, diarrhoea, constipation and reduced appetite, mostly during dose increases. Many settle; some people stop because of them. Less common serious risks in Australian Product Information include pancreatitis, gallbladder disease, dehydration leading to kidney injury, and hypoglycaemia with insulin or sulfonylureas. They are not used in pregnancy.
Anaesthesia
June 2025: TGA required class-wide warnings about inhaling stomach contents during general anaesthesia or deep sedation.
Mood
Warnings about suicidal thoughts or behaviour were aligned across the class; a causal link has not been established.
Eyes
A TGA safety update discussed reports of a rare optic nerve condition (NAION). Sudden vision change needs urgent care.
Weight regain after stopping is well documented in trial extensions, one reason these are framed as long-term treatments rather than short courses. See Ozempic side effects and Mounjaro side effects.
The role of nutrition.
Every GLP-1 registration is as an adjunct to diet and physical activity. When appetite falls sharply, the practical challenge is meeting protein, fibre, fluid and micronutrient needs from much smaller meals, and choosing foods that sit comfortably with nausea. Dietitians also watch for muscle loss alongside fat.
Preptide’s food guides cover these general principles: the GLP-1 meal plan, the GLP-1 portion guide, foods for nausea and the semaglutide food guide. Individual advice should come from a prescriber or Accredited Practising Dietitian.
Read alongside this page.
Weight loss medication in Australia: all medicines registered for chronic weight management.
Tirzepatide in Australia, Mounjaro vs Wegovy and how Mounjaro works for single-medicine detail.
Which GLP-1 medicines are available in Australia?
As of 1 October 2026: Ozempic, Wegovy and Rybelsus (semaglutide), Mounjaro (tirzepatide), Trulicity (dulaglutide) and Victoza (liraglutide). Saxenda was deleted from the market on 19 December 2025; Byetta and Bydureon (exenatide) are no longer supplied. On 3 November 2026 the TGA also registered Wegovy semaglutide tablets, which had not been released as of 9 November 2026.
Are GLP-1 medicines on the PBS in Australia?
Only for type 2 diabetes, through Ozempic and Trulicity under authority criteria. None is subsidised for weight management as of 9 November 2026. A restricted Wegovy listing was recommended in November 2025 but did not commence; a revised Wegovy proposal went to the PBAC meeting of 4 to 6 November 2026, and its outcome had not been published as of 9 November 2026.
How many Australians use GLP-1 medicines?
UNSW found about 500,000 people a month using GLP-1 medicines indicated for type 2 diabetes by April 2025, 8.6 times the 2020 level. IQVIA estimated just over one million people were dispensed a GLP-1-based obesity medicine in the 12 months to May 2026, all privately.
Is compounded semaglutide or tirzepatide legal in Australia?
No. Since 1 October 2024 pharmacists must not compound GLP-1 receptor agonist analogues. Only TGA-registered products may be supplied, on prescription.
What GLP-1 medicines are coming to Australia?
Wegovy semaglutide tablets were registered by the TGA on 3 November 2026 but had not been released as of 9 November 2026. Eli Lilly’s orforglipron (proposed brand Nexvound) was still under TGA evaluation on 9 November 2026. As of 1 October 2026, CagriSema was filed overseas but approved nowhere, and retatrutide remained in phase 3 trials.
What are the main side effects of GLP-1 medicines?
Nausea, vomiting, diarrhoea, constipation and reduced appetite are most common. Rarer serious risks include pancreatitis, gallbladder disease, dehydration, hypoglycaemia with insulin or sulfonylureas, and aspiration under anaesthesia. The Consumer Medicine Information lists them all.
Related explainers: Oral GLP-1 tablets in Australia · Retatrutide in Australia · Zepbound in Australia · Is Mounjaro on the PBS?
Primary sources checked for this page.
- TGA safety update: GLP-1 and dual GIP/GLP-1 medicines.
- PBAC advice on equitable access to GLP-1 obesity treatments.
- PBS: current patient fees and charges.
- Falster et al., British Journal of Clinical Pharmacology 2026.
- IQVIA white paper: obesity medications in Australia (2026).
- TGA: GLP-1 RA pharmacy compounding changes.
- TGA ARTG 522753: Wegovy semaglutide tablets, ARTG date 3 November 2026; Wegovy Product Information, revised 3 November 2026.
- PBS medicine status: Wegovy revised proposal (case a1305); PBAC November 2026 agenda.
- TGA Medicine Shortage Reports Database: liraglutide (Saxenda discontinued, retrieved 9 November 2026).
- TGA: orforglipron (Nexvound) under evaluation.
- TGA: Wegovy registration (cardiovascular indication).
- TGA: unapproved peptide compliance focus (June 2026).
- ABC News: Wegovy to be added to the PBS (January 2026).
Editorial method: Australian regulatory sources (TGA, PBS, Department of Health) were checked first, then peer-reviewed research and industry data. Status statements are dated and may change. A named clinical review is pending; until then this is editorial research, not clinical opinion. See the Preptide editorial policy.
Important: General information only, not medical advice. Brand names are registered trademarks of their respective owners; Preptide is independent and is not affiliated with, endorsed by or sponsored by any medicine manufacturer. Preptide is food, not medication, and does not prescribe, sell, recommend or promote prescription medicines. Talk to your doctor or pharmacist about any medicine. In an emergency call 000. Read our editorial policy and Health Acknowledgement.





